Is Sarilumab on the market?

Sarilumab trade nameKevzara is a human monoclonal antibody drug against interleukin-6 receptor. Regeneron Pharmaceuticals and Sanofi developed a drug for the treatment of rheumatoid arthritis (RA), which was approved by the U.S. Food and Drug Administration (FDA) on May 22, 2017 and by the European Medicines Agency on June 23, 2017.

Salirumab is indicated for the treatment of patients with moderately to severely active rheumatoid arthritis (RA) who are unresponsive to or intolerant to conventional treatments, either alone or in combination with methotrexate or other disease-modifying antirheumatic drugs (DMARDs). In the EU, salirumab is contraindicated in patients with active severe infection. Although this is not listed as a contraindication under U.S. Food and Drug Administration approval, there is a boxed warning recommending testing for latent tuberculosis infection prior to treatment and monitoring for signs of infection during treatment with salirumab. Development for ankylosing spondylitis has been paused because the drug failed to show clinical benefit over methotrexate inPhase II trials.

The patent drug of Salirutumab is a new type of drug for treating diseases. It is not yet on the market in China, and therefore it is not covered by medical insurance. Salirumab The common dosage form of the original drug is injection, which has been marketed overseas. The European version of specifications200mg*2 bottles is priced around 17,500 per box (The price may fluctuate due to exchange rates). There are currently no generics of Salirumab produced in other countries.